Berkeley Lights, Inc. (BLI)
| Previous Close | 1.2750 |
| Open | 1.2800 |
| Bid | 0.0000 x 3100 |
| Ask | 0.0000 x 1400 |
| Day's Range | 1.1450 - 1.3000 |
| 52 Week Range | 1.1400 - 7.7900 |
| Volume | |
| Avg. Volume | 839,235 |
| Market Cap | 86.609M |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Berkeley Lights to Participate at the 27th European Society for Animal Cell Technology Meeting
Lonza and Edinburgh Genome Foundry to present their high-throughput single-cell screening workflow use cases using the Beacon® PlatformEMERYVILLE, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the 27th Annual European Society for Animal Cell Technology (ESCAT), being held from June 26 - 29, 2022 at the Lisbon Congress Centre in Lisbon, Portugal. This year’s conference, with the motto, “Advance
- Business Wire
Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities
EMERYVILLE, Calif. & ALBANY, N.Y., June 06, 2022--Curia now provides a comprehensive portfolio of state-of-the-art technologies and experience for rapid progression of client antibody programs.
- GlobeNewswire
Berkeley Lights Reports First Quarter 2022 Financial Results
EMERYVILLE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Delivered total revenue of $20.2 million for the first quarter of 2022, representing growth of 8.5% year over yearSigned a strategic partnership agreement with Vestaron to develop pesticidal peptides using the Company’s Beacon® platform and proprietary high-throughput, functional screen
